357 related articles for article (PubMed ID: 19515851)
61. RNP2 of RNA recognition motif 1 plays a central role in the aberrant modification of TDP-43.
Takagi S; Iguchi Y; Katsuno M; Ishigaki S; Ikenaka K; Fujioka Y; Honda D; Niwa J; Tanaka F; Watanabe H; Adachi H; Sobue G
PLoS One; 2013; 8(6):e66966. PubMed ID: 23840565
[TBL] [Abstract][Full Text] [Related]
62. Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS.
Inukai Y; Nonaka T; Arai T; Yoshida M; Hashizume Y; Beach TG; Buratti E; Baralle FE; Akiyama H; Hisanaga S; Hasegawa M
FEBS Lett; 2008 Aug; 582(19):2899-904. PubMed ID: 18656473
[TBL] [Abstract][Full Text] [Related]
63. Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration.
Gendron TF; Josephs KA; Petrucelli L
Neuropathol Appl Neurobiol; 2010 Apr; 36(2):97-112. PubMed ID: 20202122
[TBL] [Abstract][Full Text] [Related]
64. Poly(ADP-ribose) Engages the TDP-43 Nuclear-Localization Sequence to Regulate Granulo-Filamentous Aggregation.
McGurk L; Gomes E; Guo L; Shorter J; Bonini NM
Biochemistry; 2018 Dec; 57(51):6923-6926. PubMed ID: 30540446
[TBL] [Abstract][Full Text] [Related]
65. TDP-43: an emerging new player in neurodegenerative diseases.
Wang IF; Wu LS; Shen CK
Trends Mol Med; 2008 Nov; 14(11):479-85. PubMed ID: 18929508
[TBL] [Abstract][Full Text] [Related]
66. Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies.
Iguchi Y; Katsuno M; Takagi S; Ishigaki S; Niwa J; Hasegawa M; Tanaka F; Sobue G
Neurobiol Dis; 2012 Mar; 45(3):862-70. PubMed ID: 22198567
[TBL] [Abstract][Full Text] [Related]
67. Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43.
Nishimoto Y; Ito D; Yagi T; Nihei Y; Tsunoda Y; Suzuki N
J Biol Chem; 2010 Jan; 285(1):608-19. PubMed ID: 19887443
[TBL] [Abstract][Full Text] [Related]
68. Asparaginyl endopeptidase cleaves TDP-43 in brain.
Herskowitz JH; Gozal YM; Duong DM; Dammer EB; Gearing M; Ye K; Lah JJ; Peng J; Levey AI; Seyfried NT
Proteomics; 2012 Aug; 12(15-16):2455-63. PubMed ID: 22718532
[TBL] [Abstract][Full Text] [Related]
69. A unique mouse model for investigating the properties of amyotrophic lateral sclerosis-associated protein TDP-43, by in utero electroporation.
Akamatsu M; Takuma H; Yamashita T; Okada T; Keino-Masu K; Ishii K; Kwak S; Masu M; Tamaoka A
Neurosci Res; 2013 Dec; 77(4):234-41. PubMed ID: 24080146
[TBL] [Abstract][Full Text] [Related]
70. Age-related deregulation of TDP-43 after stroke enhances NF-κB-mediated inflammation and neuronal damage.
Thammisetty SS; Pedragosa J; Weng YC; Calon F; Planas A; Kriz J
J Neuroinflammation; 2018 Nov; 15(1):312. PubMed ID: 30413172
[TBL] [Abstract][Full Text] [Related]
71. Identification and characterization of ubiquitinylation sites in TAR DNA-binding protein of 43 kDa (TDP-43).
Hans F; Eckert M; von Zweydorf F; Gloeckner CJ; Kahle PJ
J Biol Chem; 2018 Oct; 293(41):16083-16099. PubMed ID: 30120199
[TBL] [Abstract][Full Text] [Related]
72. The Effect of Different Types of Nanoparticles on FUS and TDP-43 Solubility and Subcellular Localization.
Lojk J; Prpar Mihevc S; Bregar VB; Pavlin M; Rogelj B
Neurotox Res; 2017 Oct; 32(3):325-339. PubMed ID: 28444573
[TBL] [Abstract][Full Text] [Related]
73. The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates.
Wang YT; Kuo PH; Chiang CH; Liang JR; Chen YR; Wang S; Shen JC; Yuan HS
J Biol Chem; 2013 Mar; 288(13):9049-57. PubMed ID: 23372158
[TBL] [Abstract][Full Text] [Related]
74. Allele-specific knockdown of ALS-associated mutant TDP-43 in neural stem cells derived from induced pluripotent stem cells.
Nishimura AL; Shum C; Scotter EL; Abdelgany A; Sardone V; Wright J; Lee YB; Chen HJ; Bilican B; Carrasco M; Maniatis T; Chandran S; Rogelj B; Gallo JM; Shaw CE
PLoS One; 2014; 9(3):e91269. PubMed ID: 24651281
[TBL] [Abstract][Full Text] [Related]
75. Formation and spreading of TDP-43 aggregates in cultured neuronal and glial cells demonstrated by time-lapse imaging.
Ishii T; Kawakami E; Endo K; Misawa H; Watabe K
PLoS One; 2017; 12(6):e0179375. PubMed ID: 28599005
[TBL] [Abstract][Full Text] [Related]
76. Profilin 1 mutants form aggregates that induce accumulation of prion-like TDP-43.
Tanaka Y; Hasegawa M
Prion; 2016 Jul; 10(4):283-9. PubMed ID: 27432186
[TBL] [Abstract][Full Text] [Related]
77. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity.
Boyd JD; Lee P; Feiler MS; Zauur N; Liu M; Concannon J; Ebata A; Wolozin B; Glicksman MA
J Biomol Screen; 2014 Jan; 19(1):44-56. PubMed ID: 24019256
[TBL] [Abstract][Full Text] [Related]
78. Metabolism and mis-metabolism of the neuropathological signature protein TDP-43.
Huang CC; Bose JK; Majumder P; Lee KH; Huang JT; Huang JK; Shen CK
J Cell Sci; 2014 Jul; 127(Pt 14):3024-38. PubMed ID: 24860144
[TBL] [Abstract][Full Text] [Related]
79. Comparative analysis of thermal unfolding simulations of RNA recognition motifs (RRMs) of TAR DNA-binding protein 43 (TDP-43).
Prakash A; Kumar V; Meena NK; Hassan MI; Lynn AM
J Biomol Struct Dyn; 2019 Jan; 37(1):178-194. PubMed ID: 29279008
[TBL] [Abstract][Full Text] [Related]
80. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity.
Johnson BS; McCaffery JM; Lindquist S; Gitler AD
Proc Natl Acad Sci U S A; 2008 Apr; 105(17):6439-44. PubMed ID: 18434538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
